NCT07181720 2025-10-02
CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
Chongqing Precision Biotech Co., Ltd
Phase 1 Recruiting
Clinical Trials
12 trialsNCT04418167 2025-09-03
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
JS InnoPharm, LLC
Phase 1 Suspended
NCT04579757 2025-05-08
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
Phase 1/2 Terminated
NCT04420754 2025-03-30
Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer
AffyImmune Therapeutics, Inc.
Phase 1 Active not recruiting
NCT02034110 2023-08-21
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
Phase 2 Completed
NCT02404441 2022-08-03
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Novartis
Phase 1/2 Completed
NCT02012231 2020-10-19
Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
Fore Biotherapeutics
Phase 1 Terminated
NCT04574817 2020-10-05
Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)
Taizhou Hanzhong biomedical co. LTD
Phase 2 Unknown
NCT00603941 2020-09-16
A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel
Daiichi Sankyo
Phase 1/2 Terminated
NCT02657369 2019-10-15
A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
Eisai Inc.
Phase 2 Terminated
NCT00507429 2014-06-09
FACT
Mateon Therapeutics
Phase 2/3 Terminated
NCT01701349 2014-05-01
FACT2
Mateon Therapeutics
Phase 3 Withdrawn